On May 26, 2020 Burning Rock Biotech, a Guangzhou diagnostics company, reported that it filed for a NASDAQ IPO to support its precision medicine and early cancer detection business (Press release, Burning Rock Biotech, MAY 26, 2020, View Source [SID1234558474]). Founded in 2014, Burning Rock claims to be China’s leading NGS-based cancer therapy selection company with a market share of 27% in 2019. The company offers in-hospital testing in larger institutions and central laboratory testing services to smaller hospitals. Currently, Burning Rock offers 13 NGS-based cancer therapy selection tests for a broad range of cancer types, using tissue or liquid biopsy samples. The company is seeking to raise up to $100 million in the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!